Clinical trials for age-related macular degeneration

Jump to: Neovascular (wet) AMD | Geographic Atrophy (advanced dry AMD)

On this page you can find a list of active, innovative clinical trials for for age-related macular degeneration (AMD). You can find a list of clinical trials for inherited retinal diseases (IRDs) here.

Where available, the following information is included for each trial:

• Type of treatment, such as device, stem cell therapy or a drug
• Drug name (alternative or brand name in brackets)
• Trial sponsor and phase (TRIAL NAME capitalized in brackets)
• Other information including if there is a Canadian trial site, or links to research updates
• Clinicaltrial.gov number. This will link out to trial page on the clinicaltrials.gov website

You can find more information about these or other clinical trials at ClinicalTrials.gov. This website can be a good place to start your research. However, trials listed may not be approved by the FDA, meet basic safety standards or be appropriate for you. Always consult your doctor before participating in any trial.

neovascular (wet) AMD

• Drug: AXT107 (DISCOVER). AsclepiX Therapeutics, Phase 1/2, Update (2024) NCT05859776
• Drug/Device: EYP-1901 (Vorolanib), EyePoint Pharmaceuticals, Phase 3 (LUCIA) NCT06683742, Phase 3 (LUGANO), Update (2025), NCT06668064
• Drug/Device: OTX-TKI (axitinib implant), Ocular Therapeutix Inc., Phase 3, Update (2023), NCT06495918
• Gene Therapy: anti-VEGF and VEGF-C RNAi, 4D-150, 4D Molecular Therapeutics, Phase 1/2 (PRISM), NCT05197270, Update (2024), Phase 3 (4FRONT), Update (2025), NCT06864988
• Gene therapy: anti-VEGF (RGX-314) AbbVie: Phase 2 (AAVIATE), Update (2024) (2025), NCT04514653
• Gene therapy: anti-VEGF (RGX-314) AbbVie: Phase 2/3 (ATMOSPHERE) NCT04704921, Phase 3 (ASCENT), Update (2025), NCT05407636
• Gene Therapy: anti-VEGF (ADVM-022, Ixo-vec), Adverum Biotechnologies, Phase 2 (LUNA), Update (2024), NCT05536973, Phase 3 (ARTEMIS), Update (2025), NCT06856577
• Gene therapy: sCD59 (AAVCAGsCD59), Janssen, Phase 1, Completed, NCT03585556
• Gene therapy: SAR402663, Sanofi, Phase 1/2, NCT06660667

geographic atrophy (advanced Dry AMD)

• Prostheses: PRIMA System, Pixium Vision, Update (2024), NCT03392324
• Cell therapy : RPE (ASP7317), Astellas, Phase 1, NCT03178149
• Cell therapy: RPE cells (OpRegen), Genetech/Roche, Phase 2, Update (2025), NCT05626114
• Cell therapy : RPE, NEI, Phase 1/2, Update (2024), NCT04339764
• Cell therapy : RPE (CPCB-RPE1), Regenerative Patch Technologies, Phase 1/2, Update (2022), NCT02590692.
• Drug: ANX007 (ARCHER II), Annexon, Phase 3, Update (2024), NCT06510816
• Drug: AVD-104 (SIGLEC), Aviceda Therapeutics, Phase 2, Update (2024), NCT05839041
• Drug: BI 771716 (VERDANT), Boehringer Ingelheim, Phase 2, Update (2025), NCT06722157
• Drug: BI 1584862 (JADE), Boehringer Ingelheim, Phase 2, Update (2025), NCT06769048
• Drug: Elamipretide (ReNEW), Stealth BioTherapeutics, Phase 3, Update (2025), NCT06373731
• Drug: GAL-101 (eDREAM), Galimedix Therapeutics, Phase 2, Update (2025), NCT06659549
• Drug: Tinlarebant (PHOENIX), Belite Bio, Phase 3, Update (2025), NCT05949593
• Gene therapy: PST-611, Eyevensys, Phase 1, Update (2025), NCT07024732
• Gene therapy: OCU410 (ArMaDa), Ocugen, Phase 1/2, Update (2025), NCT06018558
• Photobiomodulation: LumiThera, Update (2025), (2024), NCT04065490  

If you have questions about your eye health, contact our Health Information Line at healthinfo@fightingblindness.ca or 1.888.626.2995.

This page was last updated on September 2, 2025.